Výsledky vyhledávání - "I. Goldshtien"

Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study

Autor: Shlomit Yust-Katz, Ilan Shelef, Hovav Nechushtan, Elizabeth Dudnik, Laila C. Roisman, E. Inbar, Roni Gillis, Anna Belilovski Rozenblum, I. Goldshtien, Ofer Rotem, Alona Zer, Nir Peled, L. Chen

Publikováno v: Annals of Oncology. 30:ix177-ix178

Background Osimertinib is an EGFR TKI selective for both EGFR TKI sensitizing and Thr790Met resistance mutations. While intracranial activity of osimertinib has been observed in patient subgroups within larger trials, a study focusing exclusively on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f3a80434ca054d916fb37931633b492
https://doi.org/10.1093/annonc/mdz437.054

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání